^
BIOMARKER:
HER-2 expression
i
Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
Entrez ID:
Related biomarkers:
›
HER-2 expression
|
Endometrial Adenocarcinoma
|
HER-2 expression
|
Endometrial Adenocarcinoma
|
trastuzumab Sensitive: A2 - Guideline
|
trastuzumab Sensitive: A2 - Guideline
|
HER-2 expression
|
Breast Cancer
|
HER-2 expression
|
Breast Cancer
|
ARX788 Sensitive: B - Late Trials
|
ARX788 Sensitive: B - Late Trials
|
HER-2 expression
|
Biliary Tract Cancer
|
HER-2 expression
|
Biliary Tract Cancer
|
ZW25 Sensitive: B - Late Trials
|
ZW25 Sensitive: B - Late Trials
|
HER-2 expression
|
Cholangiocarcinoma
|
HER-2 expression
|
Cholangiocarcinoma
|
trastuzumab + lapatinib Sensitive: B - Late Trials
|
trastuzumab + lapatinib Sensitive: B - Late Trials
|
HER-2 expression
|
HER2 Positive Breast Cancer
|
HER-2 expression
|
HER2 Positive Breast Cancer
|
trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria
|
trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria
|
HER-2 expression
|
Gastric Cancer
|
HER-2 expression
|
Gastric Cancer
|
trastuzumab Sensitive: C2 – Inclusion Criteria
|
trastuzumab Sensitive: C2 – Inclusion Criteria
|
HER-2 expression
|
CRC
|
HER-2 expression
|
CRC
|
fam-trastuzumab deruxtecan-nxki Sensitive: C2 – Inclusion Criteria
|
fam-trastuzumab deruxtecan-nxki Sensitive: C2 – Inclusion Criteria
|
HER-2 expression
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 expression
|
Gastroesophageal Junction Adenocarcinoma
|
fam-trastuzumab deruxtecan-nxki Sensitive: C2 – Inclusion Criteria
|
fam-trastuzumab deruxtecan-nxki Sensitive: C2 – Inclusion Criteria
|
HER-2 expression
|
Gastric Cancer
|
HER-2 expression
|
Gastric Cancer
|
A166 Sensitive: C2 – Inclusion Criteria
|
A166 Sensitive: C2 – Inclusion Criteria
|
HER-2 expression
|
Breast Cancer
|
HER-2 expression
|
Breast Cancer
|
lapatinib Sensitive: C2 – Inclusion Criteria
|
lapatinib Sensitive: C2 – Inclusion Criteria
|
HER-2 expression
|
CRC
|
HER-2 expression
|
CRC
|
A166 Sensitive: C2 – Inclusion Criteria
|
A166 Sensitive: C2 – Inclusion Criteria
|
HER-2 expression
|
HER2 Positive Breast Cancer
|
HER-2 expression
|
HER2 Positive Breast Cancer
|
A166 Sensitive: C2 – Inclusion Criteria
|
A166 Sensitive: C2 – Inclusion Criteria
|
HER-2 expression
|
HER2 Positive Breast Cancer
|
HER-2 expression
|
HER2 Positive Breast Cancer
|
avelumab Sensitive: C2 – Inclusion Criteria
|
avelumab Sensitive: C2 – Inclusion Criteria
|
HER-2 expression
|
Solid Tumor
|
HER-2 expression
|
Solid Tumor
|
fam-trastuzumab deruxtecan-nxki Sensitive: C2 – Inclusion Criteria
|
fam-trastuzumab deruxtecan-nxki Sensitive: C2 – Inclusion Criteria
|
HER-2 expression
|
Urothelial Cancer
|
HER-2 expression
|
Urothelial Cancer
|
toripalimab + disitamab vedotin Sensitive: C2 – Inclusion Criteria
|
toripalimab + disitamab vedotin Sensitive: C2 – Inclusion Criteria
|
HER-2 expression
|
Solid Tumor
|
HER-2 expression
|
Solid Tumor
|
SBT6050 Sensitive: C2 – Inclusion Criteria
|
SBT6050 Sensitive: C2 – Inclusion Criteria
|
HER-2 expression
|
Gastric Cancer
|
HER-2 expression
|
Gastric Cancer
|
AST-301 Sensitive: C2 – Inclusion Criteria
|
AST-301 Sensitive: C2 – Inclusion Criteria
|
HER-2 expression
|
Gastric Cancer
|
HER-2 expression
|
Gastric Cancer
|
disitamab vedotin Sensitive: C2 – Inclusion Criteria
|
disitamab vedotin Sensitive: C2 – Inclusion Criteria
|
HER-2 expression
|
Gastroesophageal Cancer
|
HER-2 expression
|
Gastroesophageal Cancer
|
ZW25 Sensitive: C3 – Early Trials
|
ZW25 Sensitive: C3 – Early Trials
|
HER-2 expression
|
Salivary Gland Cancer
|
HER-2 expression
|
Salivary Gland Cancer
|
ARX788 Sensitive: C3 – Early Trials
|
ARX788 Sensitive: C3 – Early Trials
|
HER-2 expression
|
CRC
|
HER-2 expression
|
CRC
|
ARX788 Sensitive: C3 – Early Trials
|
ARX788 Sensitive: C3 – Early Trials
|
HER-2 expression
|
Biliary Tract Cancer
|
HER-2 expression
|
Biliary Tract Cancer
|
ARX788 Sensitive: C3 – Early Trials
|
ARX788 Sensitive: C3 – Early Trials
|
HER-2 expression
|
NSCLC
|
HER-2 expression
|
NSCLC
|
ARX788 Sensitive: C3 – Early Trials
|
ARX788 Sensitive: C3 – Early Trials
|
HER-2 expression
|
Gastric Cancer
|
HER-2 expression
|
Gastric Cancer
|
ARX788 Sensitive: C3 – Early Trials
|
ARX788 Sensitive: C3 – Early Trials
|
HER-2 expression
|
CRC
|
HER-2 expression
|
CRC
|
panitumumab Resistant: C3 – Early Trials
|
panitumumab Resistant: C3 – Early Trials
|
HER-2 expression
|
HER2 Positive Breast Cancer
|
HER-2 expression
|
HER2 Positive Breast Cancer
|
nivolumab + fam-trastuzumab deruxtecan-nxki Sensitive: C3 – Early Trials
|
nivolumab + fam-trastuzumab deruxtecan-nxki Sensitive: C3 – Early Trials
|
HER-2 expression
|
Pancreatic Adenocarcinoma
|
HER-2 expression
|
Pancreatic Adenocarcinoma
|
trastuzumab + erlotinib + gemcitabine Sensitive: C3 – Early Trials
|
trastuzumab + erlotinib + gemcitabine Sensitive: C3 – Early Trials
|
HER-2 expression
|
CRC
|
HER-2 expression
|
CRC
|
trastuzumab + lapatinib Sensitive: C3 – Early Trials
|
trastuzumab + lapatinib Sensitive: C3 – Early Trials
|
HER-2 expression
|
Childhood B Acute Lymphoblastic Leukemia
|
HER-2 expression
|
Childhood B Acute Lymphoblastic Leukemia
|
trastuzumab Resistant: C3 – Early Trials
|
trastuzumab Resistant: C3 – Early Trials
|
HER-2 expression
|
Endometrial Cancer
|
HER-2 expression
|
Endometrial Cancer
|
fam-trastuzumab deruxtecan-nxki Sensitive: C3 – Early Trials
|
fam-trastuzumab deruxtecan-nxki Sensitive: C3 – Early Trials
|
HER-2 expression
|
Gastrointestinal Cancer
|
HER-2 expression
|
Gastrointestinal Cancer
|
pembrolizumab + margetuximab Sensitive: C3 – Early Trials
|
pembrolizumab + margetuximab Sensitive: C3 – Early Trials
|
HER-2 expression
|
Salivary Gland Cancer
|
HER-2 expression
|
Salivary Gland Cancer
|
fam-trastuzumab deruxtecan-nxki Sensitive: C3 – Early Trials
|
fam-trastuzumab deruxtecan-nxki Sensitive: C3 – Early Trials
|
HER-2 expression
|
CRC
|
HER-2 expression
|
CRC
|
cetuximab Sensitive: C3 – Early Trials
|
cetuximab Sensitive: C3 – Early Trials
|
HER-2 expression
|
Uterine Cancer
|
HER-2 expression
|
Uterine Cancer
|
fam-trastuzumab deruxtecan-nxki Sensitive: C3 – Early Trials
|
fam-trastuzumab deruxtecan-nxki Sensitive: C3 – Early Trials
|
HER-2 expression
|
Solid Tumor
|
HER-2 expression
|
Solid Tumor
|
pembrolizumab + SBT6050 Sensitive: C3 – Early Trials
|
pembrolizumab + SBT6050 Sensitive: C3 – Early Trials
|
HER-2 expression
|
CRC
|
HER-2 expression
|
CRC
|
trastuzumab + tucatinib Sensitive: D – Preclinical
|
trastuzumab + tucatinib Sensitive: D – Preclinical
|
HER-2 expression
|
HER2 Positive Breast Cancer
|
HER-2 expression
|
HER2 Positive Breast Cancer
|
paclitaxel Sensitive: D – Preclinical
|
paclitaxel Sensitive: D – Preclinical
|
HER-2 expression
|
CRC
|
HER-2 expression
|
CRC
|
tucatinib Sensitive: D – Preclinical
|
tucatinib Sensitive: D – Preclinical
|
HER-2 expression
|
Pancreatic Cancer
|
HER-2 expression
|
Pancreatic Cancer
|
afatinib Sensitive: D – Preclinical
|
afatinib Sensitive: D – Preclinical
|
HER-2 expression
|
Solid Tumor
|
HER-2 expression
|
Solid Tumor
|
ABL105 Sensitive: D – Preclinical
|
ABL105 Sensitive: D – Preclinical
|
HER-2 expression
|
Rhabdomyosarcoma
|
HER-2 expression
|
Rhabdomyosarcoma
|
T-lymphocyte cell therapy Sensitive: D – Preclinical
|
T-lymphocyte cell therapy Sensitive: D – Preclinical
|
